Flags

Earnings warning

Coherus Oncology

NMQ:CHRS · US19249H1032

BiotechnologySmall

360

Medium confidence — indicative

Value—

Profit price—

Cash yield—

Sales & asset price71

Price/Sales92

EV / Gross Profit36

Price/Book84

Quality53

Returns on capital58

Return on Capital15

Return on Equity100

Profit margins62

Cash truth not applicable for financial companies.

Growth60

Sales growth88

Profit growth51

Reinvestment1

Price momentum74

Safety61

Debt load14

Debt serviceability3

Liquidity45

Sentiment49

Analyst ratings45

Expectations trend93

Market mood37

Value Creation0/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Coherus Oncology doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2010

Employees203

Websitecoherus.com

ISINUS19249H1032

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

InflammationImmunologyOphthalmologyRheumatologyOncologyVaccinesHepatologyBiotechnologyManufacturingTherapeutics

Description

Coherus Oncology, Inc. (Coherus) operates as a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (‘PD-1’) inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline that includes tw…

Analysis

Middle-of-the-road

Coherus Oncology, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is sturdy. The company scores 0/20 on our value-creation score: not creating value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Coherus Oncology with its peers

Incyte

NSQ:INCY

CountryUSA

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Exelixis

NSQ:EXEL

CountryUSA

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Janux Therapeutics

NMQ:JANX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

MeiraGTx

NSQ:MGTX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tvardi Therapeutics

NAQ:TVRD

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Beyondspring

NAQ:BYSI

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →